The effect of atropine 0.025% on optical quality, corneal tomography, and binocular vision Artykuł oryginalny
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstrakt
Purpose: Our study pointed to evaluate the effect of atropine eye drop at 0.025% on optical quality, corneal tomography, and binocular vision.
Methods: A total of 51 university students received 0.025% atropine eye drops, once nightly to both eyes for 5 nights. Refraction, visual acuity (VA), accommodation facility, accommodation lag, near point of convergence (NPC), near point of accommodation (NPA), heterophoria, and corneal topography were measured before and after instillation.
Results: After using 0.025% atropine eye drops, the far and near heterophoria changed from -1.73 (±0.415) to -0.82 (±0.267) (p = 0.005) and -3.69 (±0.823) to 0.018 (±0.726) (p <0.001), NPC increased from 4.573 (±0.4763) to 6.625 (±0.8328) (p = 0.002), NPA increased from OD (right eye) = 11.014 (±0.4059) to 17.635 (±1.0303) (p <0.001), and OS (left eye) = 10.867 (±0.4394) to 17.110 (±0.9679) (p <0.001), Monocular estimated method (MEM) retinoscopy increased from OD = 0.848 (±0.0415) to 1.137 (±0.0570) (p <0.001), and OS = 0.892 (±0.0439) to 1.196 (±0.0570) (p <0.001), accommodation facility decreased from OD = 9.69 (±0.827) to 8.44 (±0.878) (p = 0.119), and OS = 11.01 (±0.983) to 8.69 (±0.899) (p = 0.005), near VA decreased from OD = 0.992 (±0.0055) to 0.937 (±0.0170) (p = 0.004), and OS = 0.992 (±0.0055) to 0.927 (±0.0219) (p = 0.005), pupil diameter increased from OD = 3.043 (±0.0783) to 5.121 (±0.1314) (p <0.001), and OS = 3.059 (±0.0714) to 5.253 (±0.1412) (p <0.001), far VA, central corneal thickness (CCT), corneal densitometry, corneal curvature, ocular and corneal higher order aberration (HOA) and lower order aberration (LOA) remained unchanged (all p >0.05).
Conclusions: The far and near VA, monocular accommodation facility, spherical refraction, corneal densitometry, corneal curvature, CCT, ocular and corneal HOA and LOA did not change significantly, but heterophoria, NPC, NPA, accommodative lag and pupil size changed significantly after instillation
##plugins.generic.usageStats.downloads##
##plugins.themes.bootstrap3.article.details##
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
Copyright: Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
2. Li W, Cao Y, Zhou J. Effects of low-concentration atropine eye drops on the optical quality of the eyes in myopic children. Indian J Ophthalmol. 2022; 70; 2107-10.
3. Wang J, Li Y, Musch DC et al. Progression of Myopia in School-Aged Children After COVID-19 Home Confinement. JAMA Ophthalmol. 2021; 139(3): 293-300.
4. Walline J, Smith M. Controlling myopia progression in children and adolescents. Adolesc Health Med Ther. 2015; 6, 133.
5. Voo I, Lee DA, Oelrich FO. Prevalences of ocular conditions among Hispanic, white, Asian, and black immigrant students examined by the UCLA Mobile Eye Clinic. J Am Optom Assoc. 1998; 69(4): 255-61.
6. Cui C, Li X, Lyu Y et al. Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial. Sci Rep. 2021; 11(1): 22267.
7. Kaymak H, Fricke A, Mauritz Y et al. Short-term effects of low-concentration atropine eye drops on pupil size and accommodation in young adult subjects. Graefes Arch Clin Exp Ophthalmol. 2018; 256(11): 2211-7.
8. Li H, Zhang L, Tian H et al. Effect of 0.01% Atropine on Accommodation in Myopic Teenagers. Front Pharmacol. 2022; 13: 808440.
9. Wang M, Cui C, Yu SA et al. Effect of 0.02% and 0.01% atropine on ocular biometrics: A two-year clinical trial. Front Pediatr. 2023; 11: 1095495.
10. Wu PC, Chuang MN, Choi J et al. Update in myopia and treatment strategy of atropine use in myopia control. Eye (Lond). 2019; 33(1): 3-13.
11. Fu A, Stapleton F, Wei L et al. Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression. Br J Ophthalmol. 2020; 104(11): 1535-41.
12. Bullimore MA, Lee SS, Schmid KL et al. IMI-Onset and Progression of Myopia in Young Adults. Invest Ophthalmol Vis Sci. 2023; 64(6): 2.
13. Jiang J, Long W, Hu Y et al. Accommodation and vergence function in children using atropine combined with orthokeratology. Cont Lens Anterior Eye. 2023; 46(1): 101704.
14. Bharadwaj SR, Roy S, Nandhini SP. Spasm of near reflex: Objective assessment of the near-Triad. Invest Ophthalmol Vis Sci. 2020; 61: 18.
15. Chia A, Chua WH, Cheung YB et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 2012; 119(2): 347-54.
16. Jonas JB, Ang M, Cho P et al. IMI Prevention of Myopia and Its Progression. Invest Ophthalmol Vis Sci. 2021; 62(5): 6.
17. Wang Y, Yao J, Qu X. Atropine 0.01% for the Control of Myopia in Chinese Children: Effect on Accommodation Functions and Pupil Size. J Ophthalmol. 2020; 2020: 7525180.
18. Liang C, Jnawali A, Curtin S. Effect of Low Dose Atropine Eye Drops on Ocular Structure and Function. Invest Ophthalmol Vis Sci. 2022; 63(7): 4315-A0020.
19. Allen PM, Charman WN, Radhakrishnan H. Changes in dynamics of accommodation after accommodative facility training in myopes and emmetropes. Vision Res. 2010; 50: 947-55.
20. Hiraoka T, Miyata K, Nakamura Y et al. Influences of cycloplegia with topical atropine on ocular higher-order aberrations. Ophthalmology. 2013; 120(1): 8-13.
21. Kalezic T, Vukovic I, Andjelkovic M et al. Effets des gouttes cycloplégiques sur la tomographie cornéenne. J Fr Ophtalmol. 2016; 39(10): 829-35.